Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Warts 6Melanoma 5Neoplasms 3Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Surgical Procedures, Operative 24Temozolomide 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17anlotinib 17Sirolimus 17Mesna 17Melphalan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × resiquimod × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡